Medtide Inc. (FQ2.F)
Frankfurt · EUR · Healthcare · Biotechnology
€2.10 (-0.94%) as of
Key statistics
- Market cap
- 297.78M
- P/E (TTM)
- 14.00
- EPS (TTM)
- 0.1500
- Dividend yield
- 0.00%
- 52-week range
- 1.9300 – 3.4600
- Revenue (TTM)
- 550.84M
- Profit margin
- 30.69%
- Volume
- 20.00
About Medtide Inc.
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hangzhou, China
- Employees
- 596
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.